Novavax, the Fourth American Vaccine, Nears Approval

Novavax reported results on March 11 from the clinical Phase 3 results of its (NVX-CoV2373) vaccine, showing 96% efficacy in the U.S. for mild, moderate or severe cases of COVID-19. Also, in the U.K., in a trial with 15,000 people, only 5 cases of severe COVID-19 occurred—all of them from the 7,500 people who got placebos. Efficacy there was 86%.